AbbVie’s Rinvoq: A Surging New Option for GCA Treatment
Forty percent of rheumatologists report initiating Rinvoq (upadacitinib) for giant cell arteritis (GCA) within weeks of approval, with nearly...
First Fully Robotic GI Procedure by a Gastroenterologist
In the PARADIGM pivotal IDE trial, a gastroenterologist completed the first fully robotic endoscopic submucosal dissection using EndoQuest’s Endoluminal...
RenovoRx Panther Study Progresses with First Clinical Procedure
RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont...
New Data: CNM-Au8 Improves Brain Energy Metabolism in MS
Topline data: In the combined Phase 2 REPAIR program, 12 weeks of CNM-Au8 increased the brain NAD+/NADH ratio by...
Sparrow’s Remarkable $95M To Advance Diabetes Treatment
Sparrow Pharmaceuticals raised $95 million in a Series B co-led by RA Capital Management and Forbion to advance clofutriben,...
Varmx Receives Key Phase 1 Waiver from Japan’s PMDA
Japan’s PMDA has waived the requirement for a domestic Phase 1 (ethnic bridging) study for VarmX’s VMX-C001, clearing the...
SAPU003 Trial: Full Everolimus Bioavailability for Cancer
Oral everolimus delivers roughly 10% bioavailability; Sapu003, an intravenous formulation, is designed to bypass absorption limits and deliver full...
DSMB Recommends Seastar Medical Continue Pivotal AKI Trial
Zero device-related adverse events were observed among the first 100 adult patients in SeaStar Medical’s NEUTRALIZE-AKI pivotal trial of...
New Drug Shows 86% Survival in Pancreatic Cancer Patients
Topline: In a single-arm Phase 2a cohort (N=34) of first-line pancreatic cancer, atebimetinib (IMM-1-104) plus modified gemcitabine/nab-paclitaxel delivered 86%...
Briumvi Data: Remarkable Halt to MS Disability Progression
Year 6 data from the ULTIMATE I & II open-label extensions showed an annualized relapse rate of 0.012 on...